Cancer/Tumor Profiling - Global Market Outlook (2016-2022)

August 2016 | 147 pages | ID: C004B603A3EEN
Stratistics Market Research Consulting

Abstracts

According to Stratistics MRC, the Global Cancer/Tumor Profiling market is expected to grow from $23.04 billion in 2015 to reach $78.69 billion by 2022 with a CAGR of 19.2%. Increasing cases of cancer and the need for therapy are the major factors influencing the market growth. Moreover, high investments in R&D, technological developments, and demand for safer medicines are the factors fostering the market growth. However, low awareness among clinicians about options and potential of cancer profiling are the major challenges for this market.

By application, personalized medicines segment leads the market globally with the biggest market share and is expected to grow with a high CAGR during the forecast period. The growth is attributed by unique characteristics of this segment in examining and prognosis of cancer disease. North America commands the market due to the presence of leading cancer profiling industry leaders. Asia Pacific is expected to witness huge growth due to raising incidence of cancer in this region.

Some of the key players in global Cancer/Tumor profiling market include Agendia Nv, Biotheranostics, Boreal Genomics, Inc., Caris Life Sciences, Genomic Health, Inc., Illumina, Inc., Life Technologies Corporation, Nanostring Technologies, Neogenomics Laboratories, Oncopath Laboratory, Oxford Gene Technology Ltd, Precision Therapeutics, Inc., Proteome Sciences Plc, Rational Therapeutics, and Ribomed Biotechnologies.

Applications Covered:

• Biomarker Discovery
• Diagnostics
• Personalized Medicine
• Prognosis
• Research Applications

Technologies Covered:

• Fluorescence/Chromogenic In Situ Hybridization
• Immunohistochemistry
• Microarray
• Next-Generation Sequencing
• Quantitative PCR

Regions Covered:

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• Italy
• UK
• Spain
• Rest of Europe
• Asia Pacific
• Japan
• China
• India
• Australia
• New Zealand
• Rest of Asia Pacific
• Rest of the World
• Middle East
• Brazil
• Argentina
• South Africa
• Egypt

What our report offers:

• Market share assessments for the regional and country level segments
• Market share analysis of the top industry players
• Strategic recommendations for the new entrants
• Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Contents

1 EXECUTIVE SUMMARY

2 PREFACE

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
  2.4.1 Data Mining
  2.4.2 Data Analysis
  2.4.3 Data Validation
  2.4.4 Research Approach
2.5 Research Sources
  2.5.1 Primary Research Sources
  2.5.2 Secondary Research Sources
  2.5.3 Assumptions

3 MARKET TREND ANALYSIS

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 Technology Analysis
3.8 Emerging Markets

4 PORTERS FIVE FORCE ANALYSIS

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 GLOBAL CANCER/TUMOR PROFILING MARKET, BY APPLICATION

5.1 Introduction
5.2 Biomarker Discovery
5.3 Diagnostics
5.4 Personalized Medicine
5.5 Prognosis
5.6 Research Applications

6 GLOBAL CANCER/TUMOR PROFILING MARKET, BY TECHNOLOGY

6.1 Introduction
6.2 Fluorescence/Chromogenic In Situ Hybridization
6.3 Immunohistochemistry
6.4 Microarray
6.5 Next-Generation Sequencing
6.6 Quantitative PCR

7 GLOBAL CANCER/TUMOR PROFILING MARKET, BY GEOGRAPHY

7.1 North America
  7.1.1 US
  7.1.2 Canada
  7.1.3 Mexico
7.2 Europe
  7.2.1 Germany
  7.2.2 France
  7.2.3 Italy
  7.2.4 UK
  7.2.5 Spain
  7.2.6 Rest of Europe
7.3 Asia Pacific
  7.3.1 Japan
  7.3.2 China
  7.3.3 India
  7.3.4 Australia
  7.3.5 New Zealand
  7.3.6 Rest of Asia Pacific
7.4 Rest of the World
  7.4.1 Middle East
  7.4.2 Brazil
  7.4.3 Argentina
  7.4.4 South Africa
  7.4.5 Egypt

8 KEY DEVELOPMENTS

8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 COMPANY PROFILING

9.1 Agendia Nv
9.2 Biotheranostics
9.3 Boreal Genomics, Inc.
9.4 Caris Life Sciences
9.5 Genomic Health, Inc.
9.6 Illumina, Inc.
9.7 Life Technologies Corporation
9.8 Nanostring Technologies
9.9 Neogenomics Laboratories
9.10 Oncopath Laboratory
9.11 Oxford Gene Technology Ltd
9.12 Precision Therapeutics, Inc.
9.13 Proteome Sciences Plc
9.14 Rational Therapeutics
9.15 Ribomed Biotechnologies

List Of Tables

LIST OF TABLES

1 Global Cancer/Tumor Profiling Market, By Region (2013-2022) ($MN)
2 Global Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
3 Global Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
4 Global Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
5 Global Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
6 Global Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
7 Global Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
8 Global Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
9 Global Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
10 Global Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
11 Global Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
12 Global Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
13 Global Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
14 North America Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
15 North America Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
16 North America Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
17 North America Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
18 North America Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
19 North America Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
20 North America Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
21 North America Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
22 North America Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
23 North America Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
24 North America Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
25 North America Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
26 North America Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
27 Europe Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
28 Europe Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
29 Europe Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
30 Europe Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
31 Europe Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
32 Europe Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
33 Europe Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
34 Europe Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
35 Europe Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
36 Europe Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
37 Europe Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
38 Europe Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
39 Europe Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
40 Asia Pacific Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
41 Asia Pacific Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
42 Asia Pacific Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
43 Asia Pacific Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
44 Asia Pacific Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
45 Asia Pacific Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
46 Asia Pacific Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
47 Asia Pacific Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
48 Asia Pacific Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
49 Asia Pacific Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
50 Asia Pacific Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
51 Asia Pacific Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
52 Asia Pacific Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)
53 RoW Cancer/Tumor Profiling Market, By Country (2013-2022) ($MN)
54 RoW Cancer/Tumor Profiling Market, By Application (2013-2022) ($MN)
55 RoW Cancer/Tumor Profiling Market, By Biomarker Discovery (2013-2022) ($MN)
56 RoW Cancer/Tumor Profiling Market, By Diagnostics (2013-2022) ($MN)
57 RoW Cancer/Tumor Profiling Market, By Personalized Medicine (2013-2022) ($MN)
58 RoW Cancer/Tumor Profiling Market, By Prognosis (2013-2022) ($MN)
59 RoW Cancer/Tumor Profiling Market, By Research Applications (2013-2022) ($MN)
60 RoW Cancer/Tumor Profiling Market, By Technology (2013-2022) ($MN)
61 RoW Cancer/Tumor Profiling Market, By Fluorescence/Chromogenic In Situ Hybridization (2013-2022) ($MN)
62 RoW Cancer/Tumor Profiling Market, By Immunohistochemistry (2013-2022) ($MN)
63 RoW Cancer/Tumor Profiling Market, By Microarray (2013-2022) ($MN)
64 RoW Cancer/Tumor Profiling Market, By Next-Generation Sequencing (2013-2022) ($MN)
65 RoW Cancer/Tumor Profiling Market, By Quantitative PCR (2013-2022) ($MN)